Business Description
BioLine Rx Ltd
ISIN : US09071M1062
Share Class Description:
FRA:YP2: ADRTotal Employee Number:
24Compare
Compare
Traded in other countries / regions
BLRX.IsraelBLRX.USAYP2.Germany IPO Date
2015-04-11Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.91 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.54 | |||||
Debt-to-EBITDA | -1.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -14.54 | |||||
Beneish M-Score | 10.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 53.9 | |||||
3-Year FCF Growth Rate | 53.9 | |||||
3-Year Book Growth Rate | -49.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.55 | |||||
9-Day RSI | 47.09 | |||||
14-Day RSI | 49.1 | |||||
3-1 Month Momentum % | 60.27 | |||||
6-1 Month Momentum % | 28.22 | |||||
12-1 Month Momentum % | -4.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.58 | |||||
Quick Ratio | 1.43 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 3171.65 | |||||
Days Sales Outstanding | 264.77 | |||||
Days Payable | 5037.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -41.4 | |||||
Shareholder Yield % | 63.69 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.24 | |||||
Operating Margin % | -777.29 | |||||
Net Margin % | -563.6 | |||||
EBITDA Margin % | -585.73 | |||||
FCF Margin % | -551.53 | |||||
OCF Margin % | -551.12 | |||||
ROE % | -41.45 | |||||
ROA % | -19.16 | |||||
ROIC % | -50.83 | |||||
3-Year ROIIC % | -817.74 | |||||
ROC (Joel Greenblatt) % | -906.93 | |||||
ROCE % | -31.52 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
Forward PE Ratio | 85.14 | |||||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
PS Ratio | 15 | |||||
PB Ratio | 0.79 | |||||
EV-to-EBIT | -1.04 | |||||
EV-to-EBITDA | -1.1 | |||||
EV-to-Revenue | 6.44 | |||||
EV-to-Forward-Revenue | 2.55 | |||||
EV-to-FCF | -1.16 | |||||
Earnings Yield (Greenblatt) % | -96.15 | |||||
FCF Yield % | -58.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioLine Rx Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.207 | ||
| EPS (TTM) (€) | - | ||
| Beta | 2.5166 | ||
| 3-Year Sharpe Ratio | -0.85 | ||
| 3-Year Sortino Ratio | -0.99 | ||
| Volatility % | 62.78 | ||
| 14-Day RSI | 49.1 | ||
| 14-Day ATR (€) | 0.205656 | ||
| 20-Day SMA (€) | 2.638 | ||
| 12-1 Month Momentum % | -4.7 | ||
| 52-Week Range (€) | 1.66 - 3.57 | ||
| Shares Outstanding (Mil) | 4.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioLine Rx Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-24 08:30 | In 148 days | ||
| Third quarter earnings results for 2026 | 2026-11-24 | In 147 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 45 days | ||
| General meeting for 2026 | 2026-07-29 12:00 | In 30 days | ||
| First quarter earnings conference call for 2026 | 2026-05-27 08:30 | 3.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 3.00 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-23 08:30 | 2.10 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 2.10 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 2.10 (+0.00%) |
Show
Entries
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(FRA:YP2)'s stock price today?
The current price of FRA:YP2 is €2.54. The 52 week high of FRA:YP2 is €3.57 and 52 week low is €1.66.
When is next earnings date of BioLine Rx Ltd(FRA:YP2)?
The next earnings date of BioLine Rx Ltd(FRA:YP2) is 2026-08-14 Est..
Does BioLine Rx Ltd(FRA:YP2) pay dividends? If so, how much?
BioLine Rx Ltd(FRA:YP2) does not pay dividend.
Press Release
Articles on BioLine Rx Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers